Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 16;14(4):1004.
doi: 10.3390/cancers14041004.

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

Roderick Clark  1 , Jaime Herrera-Caceres  2 , Miran Kenk  1 , Neil Fleshner  1
Affiliations
Review

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

Roderick Clark et al. Cancers (Basel). .

Abstract

Background: Prostate cancer is a leading cause of death. Approximately one in eight men who are diagnosed with prostate cancer will die of it. Since there is a large difference in mortality between low- and high-risk prostate cancers, it is critical to identify individuals who are at high-risk for disease progression and death. Germline genetic differences are increasingly recognized as contributing to risk of lethal prostate cancer. The objective of this paper is to review prostate cancer management options for men with high-risk germline mutations.

Methods: We performed a review of the literature to identify articles regarding management of prostate cancer in individuals with high-risk germline genetic mutations.

Results: We identified numerous publications regarding the management of prostate cancer among high-risk germline carriers, but the overall quality of the evidence is low.

Conclusions: We performed a review of the literature and compiled clinical considerations for the management of individuals with high-risk germline mutations when they develop prostate cancer. The quality of the evidence is low, and there is an immediate need for further research and the development of consensus guidelines to guide clinical practice for these individuals.

Keywords: clinical management; germline genetic mutations; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. U.S. Cancer Statistics Working Group U.S. Cancer Statistics Data Visualizations Tool, Based on 2019 Submission Data (1999–2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. [(accessed on 25 September 2020)]; Available online: www.cdc.gov/cancer/dataviz.
    1. Epstein M.M., Edgren G., Rider J.R., Mucci L.A., Adami H.-O. Temporal Trends in Cause of Death among Swedish and US Men with Prostate Cancer. J. Natl. Cancer Inst. 2012;104:1335–1342. doi: 10.1093/jnci/djs299. - DOI - PMC - PubMed
    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J. Clin. 2014;64:9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Pritchard C.C., Mateo J., Walsh M.F., De Sarkar N., Abida W., Beltran H., Garofalo A., Gulati R., Carreira S., Eeles R., et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. [(accessed on 5 October 2020)]. Available online: https://www.nejm.org/doi/10.1056/NEJMoa1603144. - DOI - PMC - PubMed
    1. Narod S.A., Neuhausen S., Vichodez G., Armel S., Lynch H.T., Ghadirian P., Cummings S., Olopade O., Stoppa-Lyonnet D., Couch F., et al. Rapid Progression of Prostate Cancer in Men with a BRCA2 Mutation. Br. J. Cancer. 2008;99:371–374. doi: 10.1038/sj.bjc.6604453. - DOI - PMC - PubMed

LinkOut - more resources